Published online May 20, 2017. doi: 10.5493/wjem.v7.i2.42
Peer-review started: January 21, 2017
First decision: March 8, 2017
Revised: April 24, 2017
Accepted: May 3, 2017
Article in press: May 5, 2017
Published online: May 20, 2017
Core tip: Cancer immunogene therapy is a major growing area among human clinical trials. Until August 2016 there were about 2409 registered gene therapy trials, where 1554 were aimed to cancer, and among them 864 corresponded to immunotherapy. Working with veterinary cancer bearing patients can significantly speed up translational research and benefit both veterinary and human patients. New data demonstrated the safety and efficacy of different immunotherapy approaches. Following our previously published review on the subject covering from 1996 to 2014, this new mini-review is focused on veterinary cancer immunogene therapy covering published work in the field from 2014 to 2016.